Milnacipran

Milnacipran
	Top: (1S,2R)-milnacipran (L-milnacipran); Bottom: (1R,2S)-milnacipran (D-milnacipran)
Clinical data
Trade names	Ixel, Joncia, Savella
AHFS/Drugs.com	Monograph
MedlinePlus	a609016
Pregnancy; category	AU: B3;
Routes of; administration	By mouth (tablets), capsules)
ATC code	N06AX17 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	85%
Protein binding	13%
Metabolism	Hepatic
Elimination half-life	8 hours
Excretion	Renal
Identifiers
	IUPAC name (±)-(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1- phenylcyclopropane-1-carboxamide;
CAS Number	92623-85-3 ;
PubChem CID	65833;
DrugBank	DB04896 ;
ChemSpider	59245 ;
UNII	G56VK1HF36;
KEGG	D08222 ;
ChEMBL	ChEMBL252923 ;
CompTox Dashboard (EPA)	DTXSID601025164 DTXSID3048287, DTXSID601025164 ;
Chemical and physical data
Formula	C15H22N2O
Molar mass	246.354 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C(N(CC)CC)[C@@]2(c1ccccc1)[C@@H](CN)C2;
	InChI InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1 ; Key:GJJFMKBJSRMPLA-HIFRSBDPSA-N ;
	(verify)

Milnacipran (trade names Ixel, Savella, Dalcipran, Toledomin) is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia, Major depressive disorder, and Neuropathic pain. In the US, it is solely approved for the treatment of Fibromyalgia even though it is also approved for the treatment of Major depressive disorder (but not Fibromyalgia) in others countries (e.g France)

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.